I
llicit opioid use has been a main element of illicit drug use in North America and other occidental countries for more than a century. However, while the phenomenon has typically been associated with the narrow image of the "heroin junkie" (1), the current reality of illicit opioid use has become much more diverse and complex. Illicit opioid use is associated with considerable risks and harms relating specifically to users' drug use, health, and social problems (for example, crime). Many of these characteristics contribute to the substantive disease, as well as to the social cost, burden of illicit opioid use, making it an important public health problem and underscoring the need for effective interventions (2, 3) . This paper's objectives are twofold: we selectively present key characteristics and consequences of illicit opioid use, drawing on data from Canada, Australia, Europe, and the United States; and we present corresponding data from a multisite sample of illicit opioid users in 5 Canadian cities (the OPICAN study). Finally, we discuss implications for policy and practice.
Overview

Epidemiology
The extent of illicit opioid use is typically expressed by estimates of illicit opioid user populations on a country basis. For example, in Canada, it is estimated that there are between 90 000 and 125 000 IDUs, most of whom are believed to use illicit opioids (4, 5) . The Office of National Drug Control Policy estimates that there are between 750 000 and 1 million heroin users in the United States (6) . In Australia, the number of dependent heroin users (aged 15 to 54 years) has been estimated to be about 75 000, a figure that has reportedly doubled since the mid-1980s (7) . Current estimates from the European Union suggest there are between 1.2 and 2.1 million illicit drug users and between 850 000 and 1.3 million IDUs, indicators that principally reflect opioid use (8) .
In recent years, research has suggested that illicit opioid use in known problem populations is by far not limited to heroin but, rather, increasingly includes a large and diverse amount of legally available-and illegally diverted-prescription opioids, including hydromorphone (Dilaudid), oxycodone (Oxycontin), codeine (Codeine), meperidine (Demerol), morphine (MS-Contin), and hydrocodone (Vicodin). In some populations, heroin is even completely absent from illicit opioid user profiles. For example, in a recent study of regular opioid users in Toronto, Ontario, who were neither in treatment nor actively seeking treatment, 73% indicated the use of nonheroin opioids in the past 30 days (9) . A study of illicit opioid-dependent individuals attending a large Toronto MMT program reported that oxycodone (46.6%), codeine (45.5%), morphine (21.3%), and hydromorphone (17.4%) were the most prevalently used prescription opioid drugs. A sizeable proportion of the sampled individuals were exclusively dependent on prescription opioids and had never used heroin in their lives; many attributed their ongoing opioid use to a habit that was initiated through treatment received for pain (10) .
While the expanding role of prescription opioids in these known problem populations is increasingly recognized, the focus on them may only reveal a limited view of the overall picture. In North America, staggering prevalence rates of prescription opioid misuse have been recently reported for general populations, which in terms of their epidemiologic significance far outweigh rates for street user populations. For example, 4.7% of the US household population over the age of 12 years (that is, 11.0 million people) abused an opioid medication in 2002. The annual incidence of opioid analgesic abuse in the United States increased to about 2.4 million initiates in 2001, a fourfold increase from 1990 (11) (12) (13) . This recent annual opioid abuse incidence is more than double the size of the United States' total estimated heroin user population. The massive increases in prescription opioid abuse have cooccurred with substantive increases in prescription opioid mentions in emergency department admissions and in deaths investigated by coroners in the United States (11) . Comparable systematic prescription opioid abuse data for Canada are missing (14) . For example, no items on prescription drug abuse were included in the recent Canadian Addiction Survey (15) , although recent anecdotal evidence points to similar spikes in prescription opioid misuse. Major upsurges in Oxycontin abuse have been reported in Eastern Canada, including in St John's, Newfoundland, where the number of users is growing, particularly among adolescents (16) . In both general and marginalized populations, the massive increases in prescription opioid use must certainly be understood in the context of substantially increased availability and supply in recent years. Generous opioid prescription practices in the medical system, and also their ready availability via the Internet, have facilitated a drug-rich environment in North America that allows easy misuse and diversion to illicit markets (11, 14) . According to International Narcotics Control Board data (17) , the United States is by far the world's largest consumer of prescription opioids on a per capita basis (25 993 defined daily doses of opioid per million population in the period 2001 to 2003). Canada ranks as the fifth highest consumer overall (10 209 defined daily doses) and even heads the list for specific opioids (for example, hydromorphone) (17) . Combined, the United States and Canada consume more than one-half (56.2%) of the world's morphine, most of which is used for the manufacturing of other opioid prescription drug products (17) . Clearly, an analysis of the characteristics and consequences of illicit opioid use that does not consider the extensive nonmarginalized user populations has limited utility, and a comprehensive analysis must be undertaken in the future. Currently, few data or, in the case of Canada, no data exist beyond prevalence or incidence descriptions; hence, in this paper, we limit the discussion to an overview focusing on marginalized and high-risk illicit opioid user populations.
Nonopioid Use
Marginalized opioid user populations typically do not restrict their drug use to opioids, yet they are increasingly characterized by so-called "polydrug use" profiles. Such polydrug use typically involves cocaine, benzodiazepines, and alcohol as key components. In the Toronto study conducted with regular opiate users not in treatment, 70% had used alcohol, 64% had used cannabis, 61% had used benzodiazepines, and 58% had used cocaine (9) . Among heroin users in Australia (n = 222), 65% received a lifetime diagnosis of alcohol dependence, 23% of benzodiazepine dependence, and 9% of cocaine dependence (18) .
One specific form of polydrug use is the combination of opioids and cocaine, typically referred to as "speedballing," where the 2 substances are mixed and administered by injection. This has been the preferred drug use activity in certain urban IDU populations, for example, among IDUs in Vancouver (19) . Although the combined pharmacologic properties and effects of heroin and cocaine are experienced as desirable by the user (20) , the short effect curve of cocaine typically leads to high injection frequency, or even injection binges, and consequently, a dramatically increased risk for disease transmission (due to needle-sharing) or overdose (21) (22) (23) . Further, polydrug use patterns involving the use of opioids combined with stimulants (such as cocaine, benzodiazepines, or alcohol) have problematic health consequences, since they substantially elevate the risk for (fatal or nonfatal) overdose.
In most fatal overdose cases involving illicit opioid use, at least one of these nonopioid stimulants was also present (24) (25) (26) (27) ).
However, not only drug use profiles but also the modes of drug administration have become more heterogeneous among illicit opioid users. Data from several jurisdictions, including several European countries-for example, The Netherlands and Spain-as well as from Australia and the United States, suggest that noninjection practices are increasingly prevalent or may even be the dominant route of drug administration (28) (29) (30) (31) (32) . Although opioids may be "snorted" (that is, administered intranasally) in some cases, they may also be swallowed or smoked, or their fumes may be inhaled ("chasing the dragon") (33) . Overall, noninjectors are exposed to fewer health risks and harms, compared with injectors. For example, being a noninjector has been shown to indicate lower levels and shorter duration of drug dependency (34) , lower prevalence of and fewer risks for transmission of blood-borne infectious disease (that is, HIV and HCV) (35) (36) (37) , and less exposure to overdose risks (38) . However, the oral use of opioids, that is, by way of smoke inhalation, can produce its own distinct health problems, such as pulmonary dysfunction, asthma, or leukoencephalopathy (39, 40) . Evidence from several studies indicates that many opioid users begin with noninjection and eventually switch to injection routes, motivated either by economic (for example, seeking more "efficient" modes of use) or by social network dynamics (32, 33, 41) . At the same time, opioid injectors may shift to noninjection forms in search of less risky forms of drug use or as a step in maturing out of their use habits altogether (42) . Given the substantially increased levels of risks and harms associated with injection forms of opioid use, both ends of the transition trajectory have enormously important implications for prevention, yet they are little understood or used in interventions (43) (44) (45) .
Health Characteristics
Illicit opioid users have a range of distinct mortality and morbidity characteristics, the latter category consisting of both physical and mental health dimensions. First, compared with the general population, mortality rates are substantially elevated among illicit opioid users. Mortality is caused primarily by fatal drug overdose and, to a limited extent, by the fatal consequences of infectious disease (for example, HIV and HCV). Mortality rates among illicit opioid users average 1% to 3% yearly, and several studies suggest that 20% to 30% of regular opioid users have experienced at least one nonfatal overdose incident in the past year (26, 46, 47) . Various predictors of fatal and nonfatal overdose risks have been identified, including drug injection, polysubstance use (including cocaine or benzodiazepines), housing status, or drug use shortly after terminating treatment or release from prison (24, (48) (49) (50) .
Illicit opioid users-especially past or present injectors-show highly elevated prevalence levels of blood-borne infectious disease, specifically HIV and HCV; however, these rates also vary considerably from population to population. The HIV prevalence levels in Canadian IDU populations range from 10% to 35%, whereas HCV infection levels range from 40% to 90% (51, 52) . In Canada, illicit opioid and other drug users account for about 75% of new HCV infections and 30% of new HIV infections (53, 54) . Studies on younger and (or) noninjector populations from other jurisdictions have shown rates of HCV infection as low as 38%, illustrating that infectious disease prevalence depends on risk exposure, including age or length of drug career, particular use habits (for example sharing), and the nature of social networks (55, 56) .
On the mental health side, substantially elevated rates of psychiatric disorders are prevalent in illicit opioid users, defining high levels of comorbidity in this population. Systematic reviews suggest that the prevalence of psychiatric disorders among illicit opioid users ranges from 40% to 80%, with mood disorders-primarily depression-being the most prevalent (57) (58) (59) . Other studies have also found evidence of elevated levels for other mental health disorders among illicit opioid users, including antisocial personality disorder and posttraumatic stress disorder (60) . While there is conflicting evidence regarding the association of sex and comorbidity among opioid users, antisocial personality disorder in particular has been found predominantly among male users (61).
One important implication of the presence and role of psychiatric comorbidity is that a substantial extent of illicit opioid use may need to be understood as a consequence of inadequately diagnosed or treated mental health problems-in many cases a form of depression or emotional pain from which substance users seek relief through psychoactive substance use (62, 63) . These are the main premises of the self-medication hypothesis (64) , which suggests a primary and causal link between opioid use and mood disorders. Relevant for interventions, there is also evidence that opioid users experiencing severe mental health problems are less responsive to substance use treatment and more likely to engage in high-risk behaviours related to their drug use. For example, recent studies demonstrated that users who present depressive symptoms are more likely to continue using drugs during and after treatment (65) and are more likely to inject, share injection equipment, or engage in polysubstance use (66) . Despite the high prevalence of psychiatric comorbidity among illicit opioid users, interventions comprehensively addressing comorbidity are highly limited and in dire need of improvement (67, 68) .
Socioeconomic Characteristics
Many street-involved illicit opioid users are characterized by one or more of the following socioeconomic characteristics: social marginalization (for example, inadequate housing), illegal income generation, and exposure to the criminal justice system (for example, involvement in crime or incarceration). Generally, large proportions of regular illicit opioid users are not stably housed or are homeless. About one-half of the Toronto sample of illicit opioid users fell into one of these categories (9) . A recent study in Ottawa revealed that homeless IDUs who had injected drugs in the previous 6 months were almost 7 times more likely to inject in public places (odds ratio 6.6); they were often characterized by high-risk injecting behaviour and unsterile injection equipment (69) . Frequent opioid users typically require considerable sums to finance their drug use habits and do not have sufficient employment income; consequently, many resort to alternative income sources, which usually comprise either some form of social benefit (for example, welfare, disability, or unemployment support payments) or involve an illegal activity-or combinations thereof (70) . Crimes committed by illicit opioid users to generate income typically consist of small-scale drug dealing and (or) property offenses and, to a lesser degree, sex-work activities, which are more common among female users (70) (71) (72) . An Australian study reported that 72% of illicit opioid users (n = 307) had been convicted of a minor theft offense, 74% had been convicted of drug possession, and 43% had been convicted of a violent offense (73) . In the Toronto sample of opiate users (n = 114), close to one-half (47%) had committed a property offense in the last 30 days, with the largest number reporting shoplifting or minor theft (36%); two-thirds of the sample (68%) were involved in the sale or dealing of drugs (70) . Comparative systems analysis has shown that the degree to which illicit opioid users are involved in criminal activities may depend on the extent to which social benefits programs are available and suffice to cover their drug expenditures (9, 74) . Another observed correlation is the increase in criminal activity with more severe drug dependence or more frequent drug use (75, 76) . Given the extent of criminal involvement among this population, many illicit opioid users indicate past or current involvement with the criminal justice system. Specifically, large proportions of street-involved illicit opioid users have been arrested, charged, convicted, or have a history of incarceration (9).
The above-mentioned socioeconomic characteristics are important for the broader consequences of illicit opioid use in 2 ways. First, the evidence underscores the critical linkage of social characteristics and morbidity or mortality outcomes among high-risk drug users. For example, homelessness or incarceration status have been found to predict both infectious disease transmission and overdose occurrence in illicit opioid and other drug users (50, 69, 77, 78) . Second, from a social cost perspective, the economic costs of crime (that is, victimization) and criminal justice expenditures (that is, policing, courts, and corrections) comprise most (about 80%) of the social cost burden imposed on society by illicit opioid use (79, 80) . Consequently, programs and policies with an interest in reducing this societal burden ought to support interventions that effectively lower activities and harms related to illicit opioid use in these areas.
Treatment
In Canada and other Western countries, opioid maintenance treatment has for several decades been the main treatment response for illicit opioid dependence (8, 82) . Although this has largely been limited to MMT, increased diversification of opioid maintenance treatment has been witnessed since the early 1990s and includes alternative maintenance modalities such as buprenorphine, morphine, and even injectable heroin (28, 83) . In Canada, MMT was heavily restricted owing to pressures from law enforcement and medical sectors in the 1970s; only a fundamental liberalization of treatment controls rendered it once again more broadly accessible in the mid 1990s (82) . In British Columbia, Ontario, and Quebec, the number of patients enrolled in MMT subsequently increased about fivefold. Further, several provinces (Alberta, New Brunswick, and Nova Scotia) initiated MMT programming in the past 10 years (84, 85) . Altogether, it is estimated that around 25 000 to 30 000 individuals (or 20% to 30% of the estimated illicit opioid user population) receive MMT at any given time in Canada, resulting in a user-treatment ratio that is, however, still lower than the ratio in countries with the most advanced treatment systems (28, 85) . Recent concerns relate to the quality of treatment in MMT and focus on high patient numbers as well as on the possible role of methadone in the increasing numbers of drug overdoses in Ontario (86) .
Although the much-expanded availability of MMT across Canada represents major progress for treatment, the population-wide utility of MMT as the sole treatment option is limited. Studies from various countries indicate that a large proportion-estimates range from 30% to 70%-of MMT patients stop treatment within the first 12 to 24 months (87, 88) . In Ontario, between 1996 and 2001, it was observed that a substantial proportion of MMT patients either remained in treatment for only a short period of time or reported multiple intermittent treatment episodes (89) . Hence, MMT often functions as a revolving door, with patients frequently moving in and out of treatment (89) (90) (91) . Various studies have illuminated patients' subjective experiences and discontent with MMT. Key issues include the pharmacologic properties and physical-emotional side effects of methadone, the absence of injecting, dosing, and (or) take-home restrictions, and the overall treatment requirements (92) (93) (94) . Despite highly prevalent polydrug use among illicit opioid users, MMT does not offer therapeutic value for nonopioid drug dependence; nevertheless, MMT patients are typically expected to reduce or quit their use of these substances. That said, various studies have documented that many MMT patients increase their cocaine or crack use in an attempt to countervail methadone's undesirable side effects, resulting in questionable overall treatment benefits or leading to treatment penalties up to the extreme of expulsion (88, 95, 96) .
As of 2005, buprenorphine has been licensed in Canada for use in opioid maintenance treatment (97), which will provide for some possible treatment diversification (98, 99) , although doubts have been raised about its additional treatment benefits. Systematic reviews indicate that the overall effectiveness of both high and low dosages of buprenorphine is less than that of methadone, particularly when treatment retention is a main outcome (100,101). Further, buprenorphine has been shown to be less or, at best, equally cost-effective when compared with methadone (102, 103) . The existing divergent interpretations regarding the relative merit of buprenorphine treatment (104) also illustrate that, apart from therapeutic interests, this discussion is also heavily influenced by economic and corporate interests or by the dynamics of an "opioid-treatment industry." 
Illicit Opioids in Canada: The OPICAN Study
A multisite cohort study to assess the social, health, and drug use characteristics of illicit opioid and other drug users not currently in treatment (the OPICAN study) was initiated in 2002 in the cities of Vancouver, Edmonton, Toronto, Montreal, and Quebec (108) . The study administered an identical research protocol at each site, comprising an intervieweradministered questionnaire on socioeconomic, health, and drug use indicators; a standardized mental health instrument (the CIDI-SF for depression); saliva-antibody tests for infectious disease (that is, HIV and HCV); and selected other assessment tools. Eligibility criteria included regular illicit opioid use in the past year, not being in addiction treatment in the past 6 months, and being aged 18 years or older. Recruitment was based on community-based snowball methods, that is, study recruitment posters and handouts in the community. Participants were screened by telephone for eligibility and then invited for an anonymous and confidential personal interview. Participants provided informed consent, completed a saliva confirmation test for illicit opioid use, were paid a participation fee, and were invited for follow-up assessments. Baseline data reported in this article were collected in 2002 and analyzed centrally. The overall baseline analysis sample comprised 679 subjects; specific analyses were based on reduced samples as specified in the reference studies.
Below, we present a select synopsis of results of the OPICAN study (baseline). The synopsis is based on data reported by Fischer and colleagues (108) unless otherwise indicated by way of the corresponding references.
Overview of Data and Results
Drug Use
Most study participants currently used various illicit opioids, yet they also used a range of illicit nonopioid substances. Heroin use was highly prevalent in the larger cities of Vancouver (91%) and Montreal (90%), and to a lesser extent in Toronto (53%), whereas participants in the smaller cities of Edmonton (28%) and Quebec (37%) were largely characterized by use of illicit prescription opioids (for example, hydromorphone, Demerol, or Tylenol 3 or 4). Highly prevalent other drug use included alcohol, cannabis, and benzodiazepines, as well as cocaine and crack, although for the latter, again, substantial local differences emerged. For example, cocaine use was most prevalent in the Montreal (69%) and Quebec (79%) samples, whereas crack use was most prevalent in Vancouver (87%), Edmonton (67%), and Toronto (62%). Consistently, most participants in each site reported the combined use of opioid and nonopioid drugs (for example, speedballs). Each site was home to minorities of participants who were not currently using drugs by injection (this minority was largest in Toronto, at 35%); as well, a minority of the cohort (26%) had shared injection equipment in the past month. Several in-depth analyses revealed further interesting dynamics related to drug use within the study cohort. First, a latent class analysis suggested that OPICAN cohort participants could be divided into 3 distinctly different drug-user groups characterized primarily by heroin and cocaine injection use, other opioid and benzodiazpenine use, and noninjected other opioid and crack use (109) . Second, a specific examination of those who also used crack, compared with those who did not also use crack, revealed that the former were significantly more likely to be characterized by key indicators of social and health risks or harms, including unstable housing, criminal activity, health problems, and injection risks (110) . Finally, a more detailed examination of the current noninjectors in the cohort revealed that most had an injection history and were older, suggesting that they had matured out of drug use by injection (43) .
Health Status, Risks, and Care
The OPICAN sample overall displayed considerably compromised physical health status. About one-half of respondents reported their health status to be fair or poor, and 7 of 10 participants reported at least one serious health problem (most prevalently, hepatitis and "pain"). HIV prevalence ranged from 11.8% (Quebec) to 20.3% (Vancouver); HCV prevalence ranged from 35.3% (Montreal) to 66.3% (Vancouver). About 1 in 5 participants reported that they had experienced at least a single (nonfatal) overdose incident in the 6 months prior to assessment, representing an additional health risk indicator. Further in-depth analysis of these overdose incidents revealed that they were predicted by various factors, including unstable housing, noninjection use of hydromorphone (a proxy of benzodiazepine use), and exposure to drug treatment in the past 6 months (111). A systematic comparison of the HCV-positive and HCV-negative cases in the sample demonstrated that these groups differed on several key measures, including injection history, age, opioid use combined with other drugs, recent drug treatment, and incarceration (112).
The sample also indicated a considerable prevalence of mental health issues. About one third of the sample self-reported that they had mental health problems; one-half indicated major depressive disorder symptoms according to the CIDI-SF for depression. Further in-depth analysis showed that the prevalence of depressive symptoms was predicted by female sex, white ethnicity, and site (non-Vancouver sites). In addition, depressive symptoms were associated with the health risks of sharing injection paraphernalia, having experienced an overdose in the past 6 months, and more frequent cocaine use (113) In terms of health or addiction care, about one-half of the sample had visited a walk-in clinic or emergency department in the past 6 months; 7 of 10 participants had visited a needle exchange site in that period. About one-quarter of the sample had used some form of addiction treatment in the past year, one-half of which included methadone treatment. Three of 10 participants had sought addiction treatment in the past year but were unable to find or access the care they sought.
Socioeconomic Indicators
The OPICAN cohort's average age was 35 years. Most participants were men and described their ethnicity as white. Over one-half of the sample lived in either transitional-unstable housing or were homeless. Although about 7 of 10 participants received income from some form of social benefit program (for example, welfare, disability, or social assistance), only 1 in 5 reported income from legal work. Over one-half of the sample had some form of illegal income; specifically, 27% reported drug dealing, 16% reported property crime, and 21% reported sex work or hustling activities for income generation (114) . One-half of the sample had been arrested at least once, and about 2 in 5 had been in detention in the past year. A series of in-depth analyses suggested that illegal incomegeneration activities were associated with various social and drug use factors. For example, property crime activity in the sample was predicted by frequency of heroin, cocaine, and crack use; male sex; housing status (nonpermanent); and past involvement in crime (114) .
Discussion
Several key implications arise from this review. Overall, for Canada and beyond, an epidemiologic reconceptualization of the problem of illicit opioid use is urgently needed. As shown above, illicit opioid use continues to occur in high-risk drug user populations (for example, street-drug users). Nevertheless, this use is by far not limited to these populations and is increasingly present in general (for example, household) populations, although few specific data exist for Canada on the characteristics of such use, its causes, and its consequences (11, 14, 108) . However, it is urgent to collect such data systematically, for both prevention and intervention purposes.
In looking more closely at illicit opioid use in the betterdocumented problem populations (such as street-drug users) in Canada and elsewhere, 3 key facts become evident. First, illicit opioid use has become diversified and heterogeneous in terms of the kinds of opioids consumed, with potent prescription opioids originating from the medical system playing an increasingly prevalent role (9, 12, 115) . Although heroin is central in some (primarily larger urban centre) populations, illicit opioid users almost exclusively rely on prescription opioids in other areas. There is little clarity on what determinants shape these distinct local profiles and the markets supporting them, although likely both economic and ecologic factors play a role (116) . An important implication of this observation is that illicit opioid use will only be effectively controlled when the substantial amounts of opioids flowing from the medical into the illicit distribution systems are effectively regulated.
Further, illicit opioid use evidently does not occur in isolation but, typically, within a complex profile of polysubstance use-one that, for example, specifically involves the co-use of cocaine-crack, benzodiazepines, or alcohol. Some understanding exists of the desirable interaction effects that lead users to actively seek the combination of opioid and nonopioid substances (20) . However, it is also documented that such combinations in many instances pose major additional risks for morbidity or mortality (for example, infectious disease transmission or overdose) and, hence, make interventions more urgent (5, 23, 117) . Given the epidemiologic and harm-outcome realities of illicit opioid use in the context of polydrug use, it is of great concern that existing therapeutic interventions-currently limited largely to MMT-offer few, if any, benefits for nonopioid use and, in many instances, either exacerbate nonopioid drug use or lead to treatment complications (88, 95) . With these realities in mind, the usefulness of new treatments urgently needs to be investigated and treatments that have proven to be beneficial applied. Specifically, the existing international evidence for buprenorphine maintenance as a new opioid maintenance agent introduced for Canada suggests that it has little additional value when compared with MMT. The benefits of medical heroin prescription are currently being investigated.
The health of illict opioid users is typically severely compromised, and the dynamics of comorbidities, both in the mental and in the physical health realm, are complex and a major challenge for interventions. As shown by the OPICAN study and other data, depressive symptoms and other mental health problems are disproportionately prevalent among illicit opioid users (58, 113) . Importantly, the cause-and-effect chain between these symptom areas may point in both directions, meaning that illicit opioid use may lead to mental health problems but also that mental health problems may lead to illicit opioid use (for example, via self-medication) (64, 67) . These circumstances underscore the need for extensive interventions tackling addiction and mental health comorbidities among illicit opioid users-an area that is presently highly underdeveloped and underresourced. The dynamics of comorbidity extend even further, however. As shown by the OPICAN data, opioid users with depressive symptoms indicate higher levels of injection risk behaviour (specifically, equipment sharing) and, hence, infectious disease transmission (113) . The complex comorbidity dynamics and need for tailored interventions can be illustrated from a different viewpoint. Of 4 new HCV cases in Canada, 3 are related to illicit drug use (52, 53) . Hence, providing treatment for HCV-infected illicit-drug users is essential from both a public health and a clinical perspective. Although longstanding ideological and clinical concerns about including drug users in HCV treatment have gradually been addressed (118), a key remaining issue is that depression is a major side effect of HCV pharmacotherapy-which, in the case of illicit opioid users, may initiate a vicious cycle: the onset or amplification of depression can lead to increased drug use, which in turn can lead to possible repeated exposure to HCV, rendering treatment efforts potentially futile. That said, treatment studies have indicated that such dynamics can proactively and effectively be addressed, leading to successful treatment of HCV-infected illicit drug users and low levels of subsequent reinfection-if the issue is addressed through the close collaboration of interdisciplinary experts, that is, addiction, infectious disease, and psychiatric specialists (119) (120) (121) . In other words, illicit opioid use and other drug use-related health problems typically tend not to be limited to addictive symptoms but, rather, cross different areas of the clinical and public health spectrum and, hence, require that specialist addiction services be closely integrated with other forms of health care.
Finally, on a related point, various analysis outcomes of the OPICAN data have also indicated that, rather than being limited to substance use itself, the key harms associated with illicit opioid use across Canada are crucially associated with determinant factors anchored in the social realm and environment. For example, our data have consistently shown that illicit opioid users characterized by unstable housing or criminal justice sanctions (for example, arrest or detention) are more likely to be at elevated risk for morbidity or mortality related to opioid use (111) . The role of social determinants in predicting harm outcomes among drug-using populations has also been demonstrated more broadly (69, 121, 122) . A different perspective on the interactions between individual and social harms is that most social costs related to illicit opioid use in Canada-estimated to be in the range of billions of dollars-are for crime and criminal justice expenditures (79) .
From this perspective, it would be shortsighted to interpret the harmful effects of illicit opioid use in ways narrowly restricted to the substance use at hand. These harmful effects need to be understood as the outcomes of dynamics that are partly rooted in the human-created social contexts and responses to the phenomenon. Illicit opioid use is likely to be present in Canadian society for some time, but the latter forces-whether in the form of social support, integration, or legal change-are available for conscious and intended change in the interest of improved public health and welfare. 
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